Saving changes...

Done

Error

Immunotherapy in Myeloma

Immunotherapy in Myeloma

Immunotherapy in Myeloma

Industry Specialists
Industry Specialists
on behalf of Myeloma UK

FREE
FREE
FREE

FREE
FREE
FREE

null FREE
FREE
FREE
null FREE
FREE
FREE
Normal Price: FREE FREE

Review:

Launch date: 24 Mar 2017
Expiry Date:

Last updated: 05 Sep 2018

Reference: 175778

This course is no longer available

Exam is embedded in the course
No preview available
No Exam Available

Latest User Comments

I would like to...

Course Availability

This course is only available to trainees days after purchase. It would need to be repurchased by the trainee if not completed in the allotted time period. This course is no longer available. You will need to repurchase if you wish to take the course again.

Description

In recent years, advances in the field of immuno-oncology have led to a greater understanding of how the body’s immune system can be harnessed to improve outcomes for myeloma patients.
Some of the most promising areas of research and emerging immunotherapies include specific antibodies that target tumour and immune cells, small molecule immunomodulatory drugs, tumour-specific T-cell directed therapies, immune checkpoint regulators, vaccination strategies, and oncolytic virotherapy.

With a number of immunotherapies now approved in myeloma, as well as several undergoing clinical development, it is important that clinicians are informed about the immunotherapies that are currently available, what trials are ongoing and which emerging immunotherapeutic areas show most promise.

By staying up to date with the latest research and practice in the rapidly expanding field of immunotherapy in myeloma, haematologists can help patients achieve the best possible outcomes.

Objectives

On completion of this course the learner will be able to:
1. Understand why the immune system provides a useful target for novel drug development in Myeloma
2. Distinguish between the different mechanisms of action of emerging immunotherapeutic approaches
3. Discuss the current state of immunotherapy in myeloma
Industry Specialists

Author Information Play Video Bio

Industry Specialists
on behalf of Myeloma UK

Dr Chris Parrish
Consultant haematologist
St James’s University Hospital
Leeds, UK

Prof Michel Delforge
Professor of Medicine
University of Leuven
Leuven, Belgium

Dr Rakesh Popat
Consultant haematologist
University College Hospitals
London, UK

Eric Low OBE
Chief Executive
Myeloma UK
Edinburgh, UK

Current Accreditations

This course has been certified by or provided by the following Certified Organization/s:

Faculty and Disclosures

Additional Contributors

Conflicts Declared

Conflicts of Interest declaration by Author:

null

User Reviews (0)

Go Back

Loading...


Saving changes...

Done

Error